US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kurv Yield Premium Strategy Tesla (TSLA) ETF

20.45

+0.15000.74%

Volume:19.52K

Turnover:396.20K

Market Cap:23.11M

PE:- -

High:20.55

Open:20.32

Low:19.93

Close:20.30

Loading ...

Overview Company News Filings

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Upstream Bio announces presentation of data on verekitug’s TSLP receptor

Press Release: Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

Press Release: Harbour BioMed Reports Full Year 2024 Financial Results

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Kelun Pharmaceutical Gives Windward Bio Worldwide Commercial Rights for Anti-thymic Drug

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TSLP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TSLP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TSLP\",,,,,undefined,":{"symbol":"TSLP","market":"US","secType":"STK","nameCN":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","latestPrice":20.45,"timestamp":1753214400000,"preClose":20.3,"halted":0,"volume":19516,"delay":0,"floatShares":1130000,"shares":1130000,"eps":0,"marketStatus":"Post-Mkt","change":0.15,"latestTime":"07-22 16:03:58 EDT","open":20.32,"high":20.55,"low":19.93,"amount":396201.900142,"amplitude":0.030542,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1753228800000},"marketStatusCode":4,"adr":0,"exchange":"AMEX","adjPreClose":20.3,"sharesOutstanding":1130000,"nav":20.34,"aum":22984200,"dividendRate":0.438142,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":20.3,"preClose":20.3,"latestTime":"08:43 EDT","volume":1087,"amount":22066.100000000002,"timestamp":1753188187143},"volumeRatio":0.931089,"impliedVol":0.3977,"impliedVolPercentile":0.724},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TSLP\",,,,,undefined,":{"symbol":"TSLP","floatShares":1130000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.931089,"shares":1130000,"dividePrice":8.96,"high":20.55,"amplitude":0.030542,"preClose":20.3,"low":19.93,"week52Low":15.36,"pbRate":"--","week52High":34.2895,"institutionHeld":0,"latestPrice":20.45,"eps":0,"divideRate":0.438142,"volume":19516,"delay":0,"ttmEps":0,"open":20.32,"prevYearClose":30.27,"prevWeekClose":20.32,"prevMonthClose":20.31,"prevQuarterClose":20.31,"fiveDayClose":19.51,"twentyDayClose":21.85,"sixtyDayClose":18.2579},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TSLP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2549549905","title":"Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2549549905","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549549905?lang=en_us&edition=fundamental","pubTime":"2025-07-08 19:00","pubTimestamp":1751972400,"startTime":"0","endTime":"0","summary":"– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for vere","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/08/3111591/0/en/Upstream-Bio-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-Verekitug-in-Chronic-Obstructive-Pulmonary-Disease-COPD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLP"],"gpt_icon":1},{"id":"2543617943","title":"Upstream Bio announces presentation of data on verekitug’s TSLP receptor","url":"https://stock-news.laohu8.com/highlight/detail?id=2543617943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543617943?lang=en_us&edition=fundamental","pubTime":"2025-06-16 08:30","pubTimestamp":1750033816,"startTime":"0","endTime":"0","summary":"Upstream Bio (UPB) announced the presentation of translational pharmacology modeling data supporting verekitug’s Thymic Stromal Lymphopoietin, TSLP...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/upstream-bio-announces-presentation-of-data-on-verekitugs-tslp-receptor-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/upstream-bio-announces-presentation-of-data-on-verekitugs-tslp-receptor-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSLP","BK4139","UPB"],"gpt_icon":0},{"id":"2534241948","title":"Press Release: Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2534241948","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534241948?lang=en_us&edition=fundamental","pubTime":"2025-05-12 18:05","pubTimestamp":1747044300,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results. Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling. First patient dosed in Phase 1b trial of APG777 in mild-to-moderate asthma with readout expected in 1H 2026. APG279 on track to initiate Phase 1b head-to-head trial vs DUPIXENT in 2025 with readout expected in 2H 2026. Positive interim Phase 1b readout of APG808 in patients with mild-to-moderate asthma demonstrated rapid, robust and sustained suppression of FeNO, a biomarker of Type 2 inflammation that is associated with exacerbations in asthma. $681.4 million cash, cash equivalents and marketable securities supports runway into Q1 2028. Apogee conducted third-party quantitative market research in April","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","LU2065732104.USD","TSLP","BK4139","BK4097","PRGS","APGE","BK4218","PK"],"gpt_icon":0},{"id":"2532683802","title":"AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2532683802","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532683802?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:01","pubTimestamp":1746129660,"startTime":"0","endTime":"0","summary":"THOUSAND OAKS, Calif., May 1, 2025 /PRNewswire/ -- Amgen  today announced financial results for the first quarter of 2025.\"Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects,\" said Robert A. Bradway, chairman and chief executive officer.For the first quarter, total revenues increased 9% to $8.1 billion in comparison to the first quarter of 2024.Product sales grew 11%, primarily driven by 14% volume growth, partially offset by 6% lower net selling price. U.S. sales grew 14%.Fourteen products delivered at least double-digit sales growth in the first quarter, includingRepatha , BLINCYTO , TEZSPIRE , EVENITY , TAVNEOS  and UPLIZNA .Non-GAAP EPS increased 24% from $3.96 to $4.90, driven by higher revenues, partially offset by higher operating expenses.Repatha  sales increased 27% year-over-year to $656 million in the first quarter, pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2025-200100246.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2025-200100246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","IE00B4R5TH58.HKD","BK4139","LU2242646821.SGD","BK4160","BK4585","BK4205","LU2468319806.SGD","BK4200","AMGN","BK4599","LU0868494617.USD","LU1057294990.SGD","MTA","PN","BK4566","BK4581","LU0289739699.SGD","LU2112291526.USD","LU0889565916.HKD","SLE","LU1983299246.USD","LU0058720904.USD","IE00BFTCPJ56.SGD","MPA","BK4534","BK4096","LU1023059063.AUD","BK4233","LU1061106388.HKD","FCF","TSLP","BK4588","LU2089984988.USD","SG9999001440.SGD","BK4533","BK4077","BK4188","IE00B2B36J28.USD","LU0109394709.USD","GIPR","TCS","LU0320765992.SGD","LU0122379950.USD","LU2242652126.USD","IE0002141913.USD","IE0009355771.USD","TCI","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2529637228","title":"Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2529637228","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529637228?lang=en_us&edition=fundamental","pubTime":"2025-04-22 18:59","pubTimestamp":1745319540,"startTime":"0","endTime":"0","summary":"- Initiation of Upcoming Phase 1a/1b Clinical Trial Expected in the Second Quarter of 2025 -. WAYNE, Pa, April 22, 2025  -- Aclaris Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration  has cleared its Investigational New Drug  application for a Phase 1a/1b clinical trial of ATI-052, a potential best-in-class bispecific anti-TSLP/IL-4R monoclonal antibody.ATI-052 is an investigational, potential best-in-class anti-TSLP/IL-4R bispecific monoclonal antibody being developed to treat certain immuno-inflammatory diseases. ATI-052 targets thymic stromal lymphopoietin  and interleukin-4 receptor  that blocks both the upstream TSLP receptor signal transduction and downstream IL-4R activation which inhibits both IL-4 and IL-13 signaling, thereby inhibiting this central proinflammatory pathway and potentially offering enhanced efficacy through dua","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aclaris-therapeutics-secures-u-food-105900381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZL793.SGD","LU1878469433.USD","ACRS","IE0031619046.USD","LU2065731478.USD","BK4006","IE00B66KJ199.SGD","ATI","BK4007","IE00B19Z4B17.USD","TSLP"],"gpt_icon":0},{"id":"2523191987","title":"Press Release: Harbour BioMed Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2523191987","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523191987?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:13","pubTimestamp":1743415980,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025. CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed , a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its financial results for the year ended December 31, 2024.Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed,  commented: \"The year 2024 was a pivotal period for Harbour BioMed, marked by significant progress in research and development, strategic business expansion, and operational excellence. Despite a challenging macroeconomic environment, the Company demonstrated remarkable resilience, navigating inflationary pressures, global supply chain disruptions, and geopolitical uncertainties while remaining focused on its long-term growth objectives.Compared to 2023, the company's revenue sustainability has continued to improve. Annual recurring revenue in","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK1583","BK4099","R","BK4213","SD","02142","BK4585","TM","TSLP","BK1161","BK4555","BK4022","BK4588","BK1574","BK4232","BK4604"],"gpt_icon":0},{"id":"2516635849","title":"Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516635849","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516635849?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:01","pubTimestamp":1741006860,"startTime":"0","endTime":"0","summary":"- CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin -- Phase 1 study in healthy volunteers ongoing - HAMPTON, N.J., March  03, 2025  (GLOBE NEWSWIRE) -- Celldex Therapeutic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035595/24180/en/Celldex-Therapeutics-Presents-Positive-Preclinical-Data-from-Inflammatory-Bispecific-Antibody-Program-CDX-622-at-AAAAI-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLP","CDX","CLDX","BK4139"],"gpt_icon":0},{"id":"2516684183","title":"Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516684183","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516684183?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:05","pubTimestamp":1740999900,"startTime":"0","endTime":"0","summary":"Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035381/0/en/Apogee-Therapeutics-Provides-Pipeline-Progress-and-Reports-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","PK","BK4139","BK4181","PD","BK4218","BK4097","PRGS","TSLP","APGE","LU2065732104.USD","BK4023","LU1169589451.USD"],"gpt_icon":0},{"id":"2516564150","title":"POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS","url":"https://stock-news.laohu8.com/highlight/detail?id=2516564150","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516564150?lang=en_us&edition=fundamental","pubTime":"2025-03-02 06:30","pubTimestamp":1740868200,"startTime":"0","endTime":"0","summary":"Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery. Data Published in NEJM and Presented at AAAAI/WAO 2025. THOUSAND OAKS, Calif., March 1, 2025 /PRNewswire/ -- Amgen  and AstraZeneca today announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE significantly reduced nasal polyp severity, the need for surgery and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps  compared to placebo.1,2 The data were published today in the New England Journal of Medicineand were highlighted as a late-breaking oral presentation during the American Academy of Allergy Asthma & Immunology /World Allergy Organization  Joint Congress in San Diego.1,2. \"Chronic rhinosinusitis with nasal polyps is a recurrent condition often requiring repeat courses of systemic corticosteroids, even for patients on currently available biologics, and can require repeat surgeries,\" said Jay Bradner, M.D., executi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/positive-results-tezspire-tezepelumab-ekko-223000167.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/positive-results-tezspire-tezepelumab-ekko-223000167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0034224299.USD","LU2242652126.USD","BK4534","SG9999014484.SGD","LU0516422952.EUR","SG9999004360.SGD","BK4503","LU0572939691.SGD","LU2242646821.SGD","LU0889565916.HKD","BK4581","LU1023059063.AUD","LU0261945553.USD","SG9999001440.SGD","SG9999006266.SGD","LU0572940350.SGD","SG9999002406.SGD","SG9999002620.SGD","TSS","LU0264606111.USD","LU1242518857.USD","LU0048573645.USD","LU2045819591.USD","BK4588","LU0532188223.SGD","LU0210637038.USD","LU0737861269.HKD","SG9999013460.SGD","TSLP","BK4585","LU1061106388.HKD","LU1983299246.USD","IE00BJT1NW94.SGD","FL","IE00B4R5TH58.HKD","IE0002141913.USD","LU0251143029.SGD","BK4535","BK4599","IE00BJJMRZ35.SGD","LU0516423091.SGD","SGXZ58947870.SGD","SG9999013486.USD","AMGN","LU0289739699.SGD","LU0320765992.SGD","LU1242518931.SGD","SG9999002414.USD","SG9999013478.USD"],"gpt_icon":1},{"id":"2516168564","title":"Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps","url":"https://stock-news.laohu8.com/highlight/detail?id=2516168564","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516168564?lang=en_us&edition=fundamental","pubTime":"2025-03-02 06:30","pubTimestamp":1740868200,"startTime":"0","endTime":"0","summary":"TEZSPIRE significantly reduced nasal congestion, polyp size and nearly eliminated the need for surgery in patients with chronic rhinosinusitis with nasal polyps. WAYPOINT data published in New England Journal of Medicine and highlighted as late-breaking oral presentation at AAAAI/WAO 2025. WILMINGTON, Del., March 01, 2025----Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen’s TEZSPIRE  significantly reduced nasal polyp severity, the need for subsequent surgery, and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps  compared to placebo.1,2 These data were published in the New England Journal of Medicine and presented today as a late-breaking oral presentation at the American Academy of Allergy Asthma & Immunology /World Allergy Organization  Joint Congress in San Diego, CA.1,2. Statistically significant and clinically meaningful improvements were observed across all key secondary outcomes assessed in the overall tria","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/positive-results-tezspire-phase-iii-223000077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0516423091.SGD","BK4585","LU1242518857.USD","LU2045819591.USD","BK4551","LU0516422440.USD","BK4503","SG9999014492.USD","BK4554","LU0516423174.USD","LU0979878070.USD","LU0261945553.USD","TSLP","BK4535","TSS","SG9999014484.SGD","LU0320765992.SGD","LU0516422952.EUR","BK4568","BK4566","BK4134","SG9999002620.SGD","SG9999002406.SGD","SG9999002679.SGD","LU0516422366.SGD","LU0889565916.HKD","SG9999004360.SGD","SG9999006266.SGD","SG9999001135.SGD","LU0532188223.SGD","LU0251143029.SGD","LU2456880835.USD","LU2417539215.USD","LU0572939691.SGD","IE0034224299.USD","SG9999013460.SGD","SG9999002414.USD","III","SG9999013486.USD","SG9999002604.SGD","AZN","LU1242518931.SGD","LU2236285917.USD","LU0048573645.USD","LU1829250122.USD","LU0737861269.HKD","SGXZ58947870.SGD","FL","SG9999013478.USD"],"gpt_icon":1},{"id":"2514712330","title":"Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514712330","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514712330?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:01","pubTimestamp":1740690060,"startTime":"0","endTime":"0","summary":"Enrollment ongoing in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under developmentPhase 2 barzolvolimab EOE study fully accrued; Phase 2 study initiated in atopic dermatitis; enrollme","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/27/3034268/24180/en/Celldex-Reports-Fourth-Quarter-and-Year-End-2024-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","SD","BK4139","BK4213","TSLP","PN"],"gpt_icon":0},{"id":"2503343081","title":"Kelun Pharmaceutical Gives Windward Bio Worldwide Commercial Rights for Anti-thymic Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2503343081","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503343081?lang=en_us&edition=fundamental","pubTime":"2025-01-13 11:20","pubTimestamp":1736738419,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Pharmaceutical (SHE:002422), through its subsidiaries, granted Switzerland-based Windward Bio the right to commercialize a anti-thymic stromal lymphopoietin worldwide, according to a Mon","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TSLP"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TSLP\",params:#limit:5,,,undefined,":[{"date":"2025-07-02","symbol":"TSLP","amount":0.45,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-07-02","defaultRemindTime":1751463000000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-03","payableDate":"2025-07-02","currency":"USD","dateTimestamp":1751428800000,"payDate":"2025-07-03"},{"date":"2025-06-04","symbol":"TSLP","amount":0.5,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-04","defaultRemindTime":1749043800000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-05","payableDate":"2025-06-04","currency":"USD","dateTimestamp":1749009600000,"payDate":"2025-06-05"},{"date":"2025-05-07","symbol":"TSLP","amount":0.55,"announcedDate":"2025-05-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-07","defaultRemindTime":1746624600000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-08","payableDate":"2025-05-07","currency":"USD","dateTimestamp":1746590400000,"payDate":"2025-05-08"},{"date":"2025-04-02","symbol":"TSLP","amount":0.55,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-02","defaultRemindTime":1743600600000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-03","payableDate":"2025-04-02","currency":"USD","dateTimestamp":1743566400000,"payDate":"2025-04-03"},{"date":"2025-03-05","symbol":"TSLP","amount":0.7,"announcedDate":"2025-03-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-05","defaultRemindTime":1741185000000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-06","payableDate":"2025-03-05","currency":"USD","dateTimestamp":1741150800000,"payDate":"2025-03-06"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TSLP\",market:\"US\",,,undefined,":[{"executeDate":"2023-11-22","recordDate":"2023-11-24","paymentDate":"2023-11-27","value":0.5775,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-22","value":0.6664,"currency":"USD"},{"executeDate":"2024-01-24","recordDate":"2024-01-25","paymentDate":"2024-01-26","value":0.5555,"currency":"USD"},{"executeDate":"2024-02-21","recordDate":"2024-02-22","paymentDate":"2024-02-23","value":0.313,"currency":"USD"},{"executeDate":"2024-03-20","recordDate":"2024-03-21","paymentDate":"2024-03-22","value":0.5189,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TSLP\",market:\"US\",delay:false,,,undefined,":{}}}